1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Drugs In Development, 2022, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 6 and 3 respectively.
Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Lung Transplant Rejection - Overview
- Lung Transplant Rejection - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Lung Transplant Rejection - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lung Transplant Rejection - Companies Involved in Therapeutics Development
- Amgen Inc
- Apeptico Forschung und Entwicklung GmbH
- Bristol-Myers Squibb Co
- Isopogen Pty Ltd
- Kamada Pharmaceuticals
- MimeTech Srl
- Radikal Therapeutics Inc
- TFF Pharmaceuticals Inc
- Veloxis Pharmaceuticals AS
- Lung Transplant Rejection - Drug Profiles
- alpha-1 proteinase inhibitor (human) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- belatacept - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- carfilzomib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- R-554 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- R-801 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- solnatide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Stem Cell Therapy for Lung Transplant Rejection - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tacrolimus - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tacrolimus ER - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- udonitrectag - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Lung Transplant Rejection - Dormant Projects
- Lung Transplant Rejection - Product Development Milestones
- Featured News & Press Releases
- Sep 23, 2021: TFF Pharmaceuticals announces promising topline results from phase 1 clinical trial of inhaled tacrolimus powder and progression toward phase 2 in lung transplantation
- Jul 13, 2021: TFF Pharmaceuticals announces completion of enrollment and preliminary data from its phase 1 clinical trial of Tacrolimus Inhalation Powder
- Jun 07, 2021: TFF Pharmaceuticals hosting key opinion leader perspectives on thin film freezing applications
- Oct 20, 2020: TFF Pharmaceuticals updates progress of human clinical trial with tacrolimus inhalation powder
- Jun 29, 2020: TFF Pharmaceuticals announces first human dosing with Tacrolimus inhalation powder
- Jun 18, 2020: TFF Pharmaceuticals receives orphan drug designation for Tacrolimus inhalation powder
- Oct 18, 2019: New insights into Alpha-1 Deficiency: A special scientific meeting organized by Kamada during the recent ERS congress
- Feb 06, 2019: Kamada announces additional interim results from phase 2 proof of concept clinical trial of intravenous Alpha-1 Antitrypsin treatment for prevention of Lung Transplant Rejection
- Jan 08, 2018: Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
- Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
- Oct 05, 2015: APEPTICO receives Orphan Drug Designation by European Medicines Agency
- Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
- Mar 03, 2015: APEPTICO provides update on phase IIa study of AP301 product candidate
- Jul 08, 2013: APEPTICO receives research grant from Austrian Research Promotion Agency (FFG)
- Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Lung Transplant Rejection, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Lung Transplant Rejection - Pipeline by Amgen Inc, 2022
- Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH, 2022
- Lung Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, 2022
- Lung Transplant Rejection - Pipeline by Isopogen Pty Ltd, 2022
- Lung Transplant Rejection - Pipeline by Kamada Pharmaceuticals, 2022
- Lung Transplant Rejection - Pipeline by MimeTech Srl, 2022
- Lung Transplant Rejection - Pipeline by Radikal Therapeutics Inc, 2022
- Lung Transplant Rejection - Pipeline by TFF Pharmaceuticals Inc, 2022
- Lung Transplant Rejection - Pipeline by Veloxis Pharmaceuticals AS, 2022
- Lung Transplant Rejection - Dormant Projects, 2022
- Number of Products under Development for Lung Transplant Rejection, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc
- Apeptico Forschung und Entwicklung GmbH
- Bristol-Myers Squibb Co
- Isopogen Pty Ltd
- Kamada Pharmaceuticals
- MimeTech Srl
- Radikal Therapeutics Inc
- TFF Pharmaceuticals Inc
- Veloxis Pharmaceuticals AS
